Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychiatr Serv 60:1458-1459, November 2009
doi: 10.1176/appi.ps.60.11.1458
© 2009 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
Google Scholar
* Articles by Shern, D. L.
* Articles by Moran, H.
PubMed
* PubMed Citation
* Articles by Shern, D. L.
* Articles by Moran, H.
Related Collections
* Patient Advocacy
* Health Policy and Legislation
* Depression
* Antidepressants
*Related Article

Special Section on the Implications of STAR*D

STAR*D: Helping to Close the Gap Between Science and Practice

David L. Shern, Ph.D. and Hazel Moran

Dr. Shern is president and chief executive officer of Mental Health America, 2000 N. Beauregard St., 6th Floor, Alexandria, VA 22311 (e-mail: dshern{at}mentalhealth america.net), where Ms. Moran was affiliated when this work was done. She is currently associate director of government affairs, Eisai Corp. of America, Washington, D.C. This commentary is part of a special section on the STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression) and the implications of its findings for practice and policy. Grayson S. Norquist, M.D., M.S.P.H., served as guest editor of the special section.

Practical clinical trials, such as STAR*D (Sequenced Treatment Alternatives to Relieve Depression), extend the traditional randomized controlled trial to real-world settings. Consumers and clinicians should be encouraged by STAR*D's 70% remission rate and should realize that for many participants remission required medication switching and augmentation. Policy makers should recognize the importance of easy access to a full range of treatments. Researchers should be sobered by the high attrition rate and the 30% of participants who did not achieve remission. Although more such practical trials are needed, future work must more meaningfully involve consumers in design, analysis, and interpretation.


Related Article:

November: This Month's Highlights
Psychiatr Serv 2009 60: 1425. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Psychiatr. Serv.Home page
G. S. Norquist
Introduction to the STAR*D Special Section
Psychiatr Serv, November 1, 2009; 60(11): 1437 - 1438.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org